Home Newsfeeds Barclays Maintains Overweight on Coca-Cola Europacific, Lowers Price Target to $67

Barclays Maintains Overweight on Coca-Cola Europacific, Lowers Price Target to $67

Barclays analyst Lauren Lieberman maintains Coca-Cola Europacific (NASDAQ:CCEP) with a Overweight and lowers the price target from $69 to $67.

byBenzinga Newsdesk

February 21, 2023

1 minute read

Barclays analyst Lauren Lieberman maintains Coca-Cola Europacific (NASDAQ:CCEP) with a Overweight and lowers the price target from $69 to $67.

Morgan Stanley Maintains Overweight on Inari Medical, Lowers Price Target to $93

By Benzinga Newsdesk

July 15, 11:02 AM

Morgan Stanley analyst Cecilia Furlong maintains Inari Medical (NASDAQ:NARI) with a Overweight and lowers the price target from $108 to $93.

NARI

Walgreens Explores Options for Shields Health in Potential $4B Deal As Part of Turnaround Strategy

By Vandana Singh

January 24, 11:44 AM

Walgreens' strategic move: Potential $4 billion sale of Shields Health Solutions, part of a broader financial strategy. CEO Tim Wentworth addresses challenges and cost-cutting measures.

WBA

CB Financial Services Q2 EPS $0.05 Down From $0.59 YoY

By Benzinga Newsdesk

July 28, 4:48 PM

CB Financial Services (NASDAQ:CBFV) reported quarterly earnings of $0.05 per share. This is a 91.53 percent decrease over earnings of $0.59 per share from the same period last year.

CBFV

Sigilon Therapeutics Q2 EPS $(0.44) Up From $(0.65) YoY, Sales $2.88M Up From $2.70M YoY

By Michael Horton

August 4, 6:30 PM

Sigilon Therapeutics (NASDAQ:SGTX) reported quarterly losses of $(0.44) per share. This is a 32.31 percent increase over losses of $(0.65) per share from the same period last year. The company reported $2.88 million in

SGTX

Barclays Maintains Overweight on Coca-Cola Europacific, Lowers Price Target to $67

Related Posts

Morgan Stanley Maintains Overweight on Inari Medical, Lowers Price Target to $93

Walgreens Explores Options for Shields Health in Potential $4B Deal As Part of Turnaround Strategy

CB Financial Services Q2 EPS $0.05 Down From $0.59 YoY

Sigilon Therapeutics Q2 EPS $(0.44) Up From $(0.65) YoY, Sales $2.88M Up From $2.70M YoY